Eton Pharmaceuticals, Inc. (ETON)
$3
Rating:
Recommendation:
-
| Symbol | ETON |
|---|---|
| Price | $3 |
| Beta | 1.372 |
| Volume Avg. | 0.19M |
| Market Cap | 75.674M |
| Shares () | - |
| 52 Week Range | 2.47-6.72 |
| 1y Target Est | - |
| DCF Unlevered | ETON DCF -> | |
|---|---|---|
| DCF Levered | ETON LDCF -> | |
| ROE | -62.00% | Strong Sell |
| ROA | -45.04% | Strong Sell |
| Operating Margin | - | |
| Debt / Equity | 73.32% | Buy |
| P/E | - | |
| P/B | 5.67 | Strong Buy |
Latest ETON news
About
Download (Excel)Eton Pharmaceuticals, Inc., a specialty pharmaceutical company, focuses on developing and commercializing pharmaceutical products for rare diseases. The company offers Biorphen, a phenylephrine injection for the treatment of clinically important hypotension resulting primarily from vasodilation in the setting of anesthesia; Carglumic Acid for the treatment of acute and chronic hyperammonemia due to N-acetylglutamate Synthase deficiency; and Rezipres, a ready-to-use formulation of a molecule that is indicated for the treatment of clinically important hypotension occurring in the setting of anesthesia. It also offers Alkindi Sprinkle, a replacement therapy for adrenocortical insufficiency in children under 17 years of age; EPRONTIA, a liquid formulation of topiramate; and Alaway Preservative Free, a preservative-free ophthalmic product to treat allergic conjunctivitis. In addition, the company develops Zonisamide Oral Suspension for the treatment of partial on-set seizures; Lamotrigine for Oral Suspension for the treatment of partial on-set seizures; cysteine injection; dehydrated alcohol injection; and Zeneo hydrocortisone autoinjector. Eton Pharmaceuticals, Inc. was incorporated in 2017 and is based in Deer Park, Illinois.